One missing metabolic step can turn cancer’s DNA-copying machinery into a lethal weakness

Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, a study led by UT Southwestern Medical Center researchers shows.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup